Scios Announces Positive Clinical Trial Results With Oral P38 kinase Inhibitor

Phase II Trial With Company's Novel Rheumatoid Arthritis Compound Scheduled

To Begin in Second Half of Year



Apr 30, 2001, 01:00 ET from Scios Inc.

    SUNNYVALE, Calif., April 30 /PRNewswire/ -- Scios Inc. (Nasdaq:   SCIO)
 announced today that data from a Phase Ib clinical trial indicate that
 SCIO-469, the company's novel oral p38 kinase inhibitor, was well-tolerated in
 healthy volunteers over a two week dosing period. Scios also announced that,
 based on the results of the Phase Ib trial, a Phase II human clinical trial is
 planned to begin later this year in Rheumatoid Arthritis (RA) patients.
 The objective of the randomized, double-blind, placebo-controlled, Phase Ib
 dose-ranging study was to evaluate the safety and tolerability of multiple
 oral dosing regimens of SCIO-469 in healthy volunteers.
     "We are making good progress with SCIO-469 and achieving results that meet
 our expectations at this point," said George Schreiner, M.D., Ph.D., chief
 scientific officer of Scios Inc., who presented the initial results of the
 Phase Ib trial today in London at SMI's second annual conference, Advances in
 Anti-Arthritic Agents.  "As we observed in our previous Phase Ia study,
 SCIO-469 demonstrates excellent oral bioavailability and plasma
 pharmacokinetics and is well-tolerated at a wide range of doses.  We will
 continue to evaluate SCIO-469 in Phase II studies that will begin later this
 year to further validate its potential for treating the millions of people who
 suffer from RA worldwide."
     Scios is developing SCIO-469 as a treatment for Rheumatoid Arthritis (RA).
 RA is a progressively worsening autoimmune disease of unknown origin in which
 the body's natural immune system attacks healthy joint tissue causing
 inflammation and joint damage.
     Preclinical data demonstrate that SCIO-469 inhibits p38 kinase, a
 stimulatory modulator of pro-inflammatory factors including tumor necrosis
 factor-alpha (TNF-alpha), interleukin-1 (IL-1), and cyclooxygenase-2 (COX-2),
 all of which are known to contribute to both symptoms and disease progression
 in patients with RA.  Existing protein-based products that antagonize
 TNF-alpha have been shown to markedly relieve the symptoms and retard the
 progression of RA.  As an oral inhibitor of TNF, SCIO-469 would offer more
 convenient dosing over the existing products that must be injected or infused
 in a medical office.  It also has the potential for additional benefits
 associated with its inhibition of IL-1 and COX-2.
 
     Scios Inc.
     Scios is a biopharmaceutical company developing novel treatments for heart
 failure and rheumatoid arthritis.  The company's disease-based technology
 platform integrates expertise in protein biology with combinatorial and
 medicinal chemistry to identify novel targets and rationally design
 protein-based and small-molecule compounds to treat cardiovascular and
 inflammatory diseases, two of the world's leading unmet medical needs.
 Additional information about Scios is available at its web site located at
 www.sciosinc.com and in the company's various filings with the Securities and
 Exchange Commission.
 
     The statements in this press release that are not historical facts are
 forward-looking statements that involve risks and uncertainties. These include
 uncertainties associated with the successful completion of additional studies
 with p38 kinase inhibitor, and the results of competing companies attempting
 to develop or improve other treatments for Rheumatoid Arthritis and other
 inflammatory diseases, as well as other risks detailed from time to time in
 the reports filed by Scios with the SEC, including the company's annual report
 on form 10-K for the year ended December 31, 2000.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X69051301
 
 

SOURCE Scios Inc.
    SUNNYVALE, Calif., April 30 /PRNewswire/ -- Scios Inc. (Nasdaq:   SCIO)
 announced today that data from a Phase Ib clinical trial indicate that
 SCIO-469, the company's novel oral p38 kinase inhibitor, was well-tolerated in
 healthy volunteers over a two week dosing period. Scios also announced that,
 based on the results of the Phase Ib trial, a Phase II human clinical trial is
 planned to begin later this year in Rheumatoid Arthritis (RA) patients.
 The objective of the randomized, double-blind, placebo-controlled, Phase Ib
 dose-ranging study was to evaluate the safety and tolerability of multiple
 oral dosing regimens of SCIO-469 in healthy volunteers.
     "We are making good progress with SCIO-469 and achieving results that meet
 our expectations at this point," said George Schreiner, M.D., Ph.D., chief
 scientific officer of Scios Inc., who presented the initial results of the
 Phase Ib trial today in London at SMI's second annual conference, Advances in
 Anti-Arthritic Agents.  "As we observed in our previous Phase Ia study,
 SCIO-469 demonstrates excellent oral bioavailability and plasma
 pharmacokinetics and is well-tolerated at a wide range of doses.  We will
 continue to evaluate SCIO-469 in Phase II studies that will begin later this
 year to further validate its potential for treating the millions of people who
 suffer from RA worldwide."
     Scios is developing SCIO-469 as a treatment for Rheumatoid Arthritis (RA).
 RA is a progressively worsening autoimmune disease of unknown origin in which
 the body's natural immune system attacks healthy joint tissue causing
 inflammation and joint damage.
     Preclinical data demonstrate that SCIO-469 inhibits p38 kinase, a
 stimulatory modulator of pro-inflammatory factors including tumor necrosis
 factor-alpha (TNF-alpha), interleukin-1 (IL-1), and cyclooxygenase-2 (COX-2),
 all of which are known to contribute to both symptoms and disease progression
 in patients with RA.  Existing protein-based products that antagonize
 TNF-alpha have been shown to markedly relieve the symptoms and retard the
 progression of RA.  As an oral inhibitor of TNF, SCIO-469 would offer more
 convenient dosing over the existing products that must be injected or infused
 in a medical office.  It also has the potential for additional benefits
 associated with its inhibition of IL-1 and COX-2.
 
     Scios Inc.
     Scios is a biopharmaceutical company developing novel treatments for heart
 failure and rheumatoid arthritis.  The company's disease-based technology
 platform integrates expertise in protein biology with combinatorial and
 medicinal chemistry to identify novel targets and rationally design
 protein-based and small-molecule compounds to treat cardiovascular and
 inflammatory diseases, two of the world's leading unmet medical needs.
 Additional information about Scios is available at its web site located at
 www.sciosinc.com and in the company's various filings with the Securities and
 Exchange Commission.
 
     The statements in this press release that are not historical facts are
 forward-looking statements that involve risks and uncertainties. These include
 uncertainties associated with the successful completion of additional studies
 with p38 kinase inhibitor, and the results of competing companies attempting
 to develop or improve other treatments for Rheumatoid Arthritis and other
 inflammatory diseases, as well as other risks detailed from time to time in
 the reports filed by Scios with the SEC, including the company's annual report
 on form 10-K for the year ended December 31, 2000.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X69051301
 
 SOURCE  Scios Inc.